The Archive · 6 posts
Shield your health! 🛡️ Shield Therapeutics (STX) on the LSE advances treatments for iron deficiency with unique solutions. Discover more! 🌟
Shield Therapeutics delivered $30.4 million of H1 revenue and stayed profitable, but Q2 revenue and cash declined against earlier periods.
July 30, 2026
Showing 5 of 6 posts
ACCRUFeR sales surge 54% as Shield hits positive EBIT, but $7.9M milestone flatters numbers. CFO exits, NY Medicaid risk awaits.
JoshuaMay 1, 2026
Shield Therapeutics hits profitability in 2025 as ACCRUFeR dominates the US oral iron market. Record revenue and positive cash flow mark a turnaround.
JoshuaApril 10, 2026
Shield Therapeutics hits key cash flow milestone in Q4 2025 and targets operating profit in 2026, driven by strong ACCRUFeR growth.
JoshuaJanuary 21, 2026
Shield Therapeutics' ACCRUFeR® revenue soars 153% to $29.3m in 2024, driven by US growth and strategic global expansion into Canada, Asia & Europe. On track for cash flow positivity by 2025.
JoshuaApril 24, 2025
Shield Therapeutics signs exclusive Japan deal with VITAL-NET for ACCRUFeR®, securing $665k upfront, milestones & double-digit royalties in iron deficiency market.
JoshuaApril 22, 2025
Investing
January 21, 2026